• Adefovir Workflows for HBV and OAT1 Research

  2026-08-17

  Adefovir, also called GS-0393, supports two complementary research applications: mechanistic HBV polymerase studies and quantitative OAT1 transporter profiling. This workflow-focused guide shows how to improve assay fidelity, connect concentration–response data with transport measurements, and troubleshoot common solubility, activation, and signal-quality problems.

• DiI (DiIC18(3)) Membrane Probe Guide

  2026-08-17

  DiI (DiIC18(3)) provides orange-red plasma membrane labeling for live or fixed cells and tissues, supporting membrane visualization, neuronal tracing, migration, fusion, adhesion, and lipoprotein workflows. It is insoluble in water and should not be selected for aqueous-only staining or exclusive intracellular organelle labeling.

• Hesperadin: Aurora B Kinase Inhibitor Workflow

  2026-08-15

  Hesperadin is an ATP-competitive Aurora B kinase inhibitor for separating kinase-dependent mitotic phenotypes from broader checkpoint behavior. This practical guide connects dose design, H3 Ser10 readouts, chromosome segregation analysis, and the Plk1–p31comet checkpoint framework to improve cell-cycle experiments and cancer research workflows.

• 3-Deazaadenosine hydrochloride in m6A Assays

  2026-08-15

  Use 3-Deazaadenosine hydrochloride as a mechanistic probe for SAHH-dependent methyl metabolism, with practical workflows for hepatic stellate cell activation, proliferation, inflammation, and viral research. The key advantage is pathway-level perturbation that can complement IGF2BP1/TUBB4B genetic experiments, while careful controls are required because it is not a selective inhibitor of IGF2BP1 or m6A alone.

• EZH2 Inhibitors in HPV-Associated Cervical Cancer

  2026-08-14

  The reference study examines whether EZH2 blockade can counter HPV-associated cervical cancer through coordinated effects on proliferation, apoptosis, cell-cycle control, viral oncogene expression, and epithelial–mesenchymal transition markers. Its comparison of EPZ6438 and ZLD1039 with cisplatin suggests that selective epigenetic intervention may be especially relevant to HPV-positive cells, although the preliminary in vivo evidence and cellular scope require further validation.

• Chlorogenic Acid–Metal Assemblies and Anti-Inflammation

  2026-08-14

  This 2026 study shows that chlorogenic acids can form predominantly 1:1 supramolecular complexes with iron or copper and that these assemblies suppress inflammatory responses more effectively than the parent molecules. Using LPS-stimulated RAW264.7 macrophages, the authors link the enhanced activity to inhibition of NF-κB signaling and reduced iNOS and COX-2 expression.

• Sanggenol L Ferroptosis in NSCLC: miR-26a-1-3p

  2026-08-13

  The reference study identifies sanggenol L as an inducer of ferroptosis in non-small cell lung cancer (NSCLC) and connects this response to the miR-26a-1-3p/MDM2/p53/SLC7A11 signaling axis. Its combined cellular, molecular, xenograft, and patient-derived tumor xenograft evidence provides a mechanistic framework for evaluating ferroptosis-oriented strategies while highlighting the need for additional translational validation.

• Risedronate Sodium: From FPPS Biology to Translation

  2026-08-13

  Risedronate Sodium illustrates how a validated osteoclast mechanism can become a broader translational platform spanning bone metabolism research, delivery science, and carefully bounded pulmonary or cancer research. This article connects FPPS biology with experimental design, clinical evidence, and strategic next steps.

• Radicicol Hsp90 Inhibitor Workflows

  2026-08-12

  Radicicol supports controlled Hsp90 perturbation across adipogenesis, apoptosis, inflammation, and antigen-presentation experiments. This practical guide connects assay design, dose optimization, storage, and mechanistic controls while distinguishing established product evidence from exploratory applications.

• Dibutyryl-cAMP in Endometrial Decidualization

  2026-08-12

  Dibutyryl-cAMP, sodium salt provides a controlled way to interrogate cAMP signaling pathway research during endometrial decidualization. This article translates evidence on ACSL4, fatty-acid β-oxidation, and lipid droplets into practical assay-design decisions.

• Regorafenib Suppresses Melanoma via RRM2–ERK/E2F3

  2026-08-11

  The 2024 iScience study identifies RRM2 as a mechanistically important downstream target of Regorafenib in melanoma and links its reduction to suppression of ERK/E2F3 signaling. Across melanoma cell models and an in vivo tumor model, the work connects reduced proliferation, invasion, and metastasis with enhanced apoptosis, providing a rationale for studying BAY 73-4506 beyond its established antiangiogenic activity.

• Quercetin, Hippo Signaling, and Cataract Protection

  2026-08-10

  A 2025 study links quercetin-mediated protection against cataract injury to suppression of Hippo pathway activity, improved antioxidant status, and preservation of lens epithelial-cell viability. Its combined network-pharmacology, mouse, and cell-based design offers a useful framework for testing pathway-dependent mechanisms while highlighting important limits in translating marker changes into clinical benefit.

• EZ Cap™ OVA mRNA for Immune Research

  2026-08-09

  EZ Cap™ OVA mRNA provides a defined model antigen for gene expression studies, airway hyperreactivity experiments, and vaccine development research. Its Cap 1 structure and poly(A) tail support translation-focused workflows, while low-inflammation delivery concepts from recent lipid nanoparticle research offer practical options for improving experimental design.

• Pexidartinib: Decoding TAM Biology Beyond Depletion

  2026-08-08

  Pexidartinib and PLX3397 provide a powerful framework for studying CSF1R-mediated signaling inhibition and macrophage behavior. This article explains how to distinguish macrophage depletion from SPP1-linked state changes when designing tumor microenvironment assays.

• Optimizing hiPSC Platelet Differentiation: Study Insights

  2026-08-07

  A 2026 study developed an optimized differentiation scheme for producing megakaryocytes and functional platelets from human induced pluripotent stem cells. By increasing embryoid body input, using human platelet lysate, replacing selected cytokines with small molecules, and improving megakaryocyte maturation, the protocol reduced production time and cost while increasing platelet output.

456 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page